Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris
Efstratios Vakirlis, Athanasios Kastanis, Demetrios IoannidesA’ Department of Dermatology, Aristotle University of Thessaloniki, GreeceAbstract: Psoriasis is one of the most common skin diseases. The mainstay of treatment for the vast majority of patients is topical therapy. A rising first...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2008-03-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Efstratios Vakirlis, Athanasios Kastanis, Demetrios IoannidesA’ Department of Dermatology, Aristotle University of Thessaloniki, GreeceAbstract: Psoriasis is one of the most common skin diseases. The mainstay of treatment for the vast majority of patients is topical therapy. A rising first-line treatment modality for psoriasis vulgaris is the two-compound ointment containing calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g (Dovobet®, Daivobet®, Taclonex®), which combines a vitamin D analog and a corticosteroid. This innovative formulation preserves the activity and bioavailability of the two components and many clinical studies have demonstrated that it has a greater efficacy, tolerability, and a rapid onset of action compared with its individual ingredients or tacalcitol.Keywords: psoriasis, calcipotriol/betamethasone dipropionate, dovobet, daivobet, taclonex |
|---|---|
| Item Description: | 1176-6336 1178-203X |